0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mechanism of the extremely high duplex-forming ability of oligonucleotides modified with N- tert-butylguanidine- or N- tert-butyl- N′- methylguanidine-bridged nucleic acids

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Antisense oligonucleotides (ASOs) are becoming a promising class of drugs for treating various diseases. Over the past few decades, many modified nucleic acids have been developed for application to ASOs, aiming to enhance their duplex-forming ability toward cognate mRNA and improve their stability against enzymatic degradations. Modulating the sugar conformation of nucleic acids by substituting an electron-withdrawing group at the 2′-position or incorporating a 2′,4′-bridging structure is a common approach for enhancing duplex-forming ability. Here, we report on incorporating an N- tert-butylguanidinium group at the 2′,4′-bridging structure, which greatly enhances duplex-forming ability because of its interactions with the minor groove. Our results indicated that hydrophobic substituents fitting the grooves of duplexes also have great potential to increase duplex-forming ability.

          Graphical Abstract

          Graphical Abstract

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Advances in oligonucleotide drug delivery

          Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing. As such, these molecules have potential therapeutic applications for myriad indications, with several oligonucleotide drugs recently gaining approval. However, despite recent technological advances, achieving efficient oligonucleotide delivery, particularly to extrahepatic tissues, remains a major translational limitation. Here, we provide an overview of oligonucleotide-based drug platforms, focusing on key approaches — including chemical modification, bioconjugation and the use of nanocarriers — which aim to address the delivery challenge.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Medicinal Chemistry of Therapeutic Oligonucleotides.

              Oligonucleotide-based therapeutics have made rapid progress in the clinic for treatment of a variety of disease indications. Unmodified oligonucleotides are polyanionic macromolecules with poor drug-like properties. Over the past two decades, medicinal chemists have identified a number of chemical modification and conjugation strategies which can improve the nuclease stability, RNA-binding affinity, and pharmacokinetic properties of oligonucleotides for therapeutic applications. In this perspective, we present a summary of the most commonly used nucleobase, sugar and backbone modification, and conjugation strategies used in oligonucleotide medicinal chemistry.
                Bookmark

                Author and article information

                Contributors
                Journal
                Nucleic Acids Res
                Nucleic Acids Res
                nar
                Nucleic Acids Research
                Oxford University Press
                0305-1048
                1362-4962
                25 August 2023
                18 July 2023
                18 July 2023
                : 51
                : 15
                : 7749-7761
                Affiliations
                Graduate School of Pharmaceutical Sciences, Osaka University , 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
                Graduate School of Pharmaceutical Sciences, Osaka University , 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
                Graduate School of Pharmaceutical Sciences, Osaka University , 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
                Sohyaku. Innovative Research Division , Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan
                Graduate School of Pharmaceutical Sciences, Osaka University , 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
                National Institutes of Biomedical Innovation , Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan
                Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University , 1-1 Yamadaoka, Suita, Osaka 565-0871, Japan
                Author notes
                To whom correspondence should be addressed. Tel: +81 6 6879 8201; Fax: +81 6 6879 8204; Email: yamaguchi-ta@ 123456phs.osaka-u.ac.jp
                Correspondence may also be addressed to Satoshi Obika. Tel: +81 6 6879 8200; Fax: +81 6 6879 8204; Email: obika@ 123456phs.osaka-u.ac.jp
                Author information
                https://orcid.org/0000-0003-3180-0257
                https://orcid.org/0000-0002-6842-6812
                Article
                gkad608
                10.1093/nar/gkad608
                10450189
                37462081
                3e2f7d38-cf9c-45cd-ab04-6511c834bb3e
                © The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 09 July 2023
                : 28 June 2023
                : 15 May 2023
                Page count
                Pages: 13
                Funding
                Funded by: Japan Society for the Promotion of Science, DOI 10.13039/501100001691;
                Award ID: 20K05748
                Award ID: 21K06511
                Funded by: Japan Agency for Medical Research and Development, DOI 10.13039/100009619;
                Award ID: JP19am0101084
                Award ID: JP19am0401003
                Award ID: JP21ae0121022
                Award ID: JP21ae0121023
                Award ID: JP21ae0121024
                Award ID: JP22ama121054
                Funded by: Institute for Open and Transdisciplinary Research Initiatives;
                Funded by: Hoansha Foundation, DOI 10.13039/100016923;
                Funded by: Osaka University, DOI 10.13039/501100004206;
                Categories
                AcademicSubjects/SCI00010
                Chemical Biology and Nucleic Acid Chemistry

                Genetics
                Genetics

                Comments

                Comment on this article